# A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

> **NCT03347123** · PHASE1,PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 11 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Epacadostat
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Lirilumab

## Key facts

- **NCT ID:** NCT03347123
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-21
- **Primary completion:** 2021-01-29
- **Final completion:** 2021-01-29
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** A business decision made by Incyte after analysis of data from a sister study.
- **Last updated:** 2022-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03347123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03347123, "A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03347123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*